(Total Views: 512)
Posted On: 01/09/2020 1:06:17 PM
Post# of 154879
Quite a different rate we got. Have a look at Immunomedics deal. Is currently valued at $4.19 Billion
$250 Million Agreements with Royalty Pharma
Terms of Royalty Funding & Stock Purchase Agreements include − Royalty Pharma acquiring royalty rights on global net sales of sacituzumab govitecan across all indications
a) Royalty Rate starts at 4.15% and tiers down to 1.75% based on annual sales exceeding $6 billion − Immunomedics receiving a) $175 million upfront cash payment
b) $75 million in equity investment at $17.15 per share, a >15% premium over a 15-day trailing average closing price
$250 Million Agreements with Royalty Pharma
Terms of Royalty Funding & Stock Purchase Agreements include − Royalty Pharma acquiring royalty rights on global net sales of sacituzumab govitecan across all indications
a) Royalty Rate starts at 4.15% and tiers down to 1.75% based on annual sales exceeding $6 billion − Immunomedics receiving a) $175 million upfront cash payment
b) $75 million in equity investment at $17.15 per share, a >15% premium over a 15-day trailing average closing price
(3)
(0)
